Literature DB >> 20412429

Fluoxetine-induced decrements in sexual responses of female rats and hamsters are reversed by 3α,5α-THP.

Cheryl A Frye1, Madeline E Rhodes.   

Abstract

INTRODUCTION: Sexual dysfunction, as a result of selective-serotonin reuptake inhibitor (SSRI) treatment among women, is relatively common and is a factor in medication compliance. The mechanisms that underlie these side-effects of SSRIs are not well-understood. SSRIs can alter activity of catabolic enzymes that are involved in progesterone's conversion to 5 α-pregnan-3 α-ol-20-one (3 α,5 α-THP). 3 α,5 α-THP plays a key role in female reproductive physiology and behavior. AIMS: This study aimed to determine whether 3 α,5 α-THP, in the midbrain ventral tegmental area (VTA) may be a potential mechanism for fluoxetine's reduction in sexual responding of female rodents. We hypothesized that if fluoxetine induces decrements in sexual responding in part through actions of 3 α,5 α-THP, then fluoxetine will inhibit sexual receptivity concomitant with reducing 3 α,5 α-THP levels, effects which can be reversed by 3 α,5 α-THP administration.
METHODS: Experiment 1 investigated effects of acute systemic fluoxetine [20 mg/kg intraperitoneal (IP)] and/or 3 α,5 α-THP [500 µg, subcutaneous (SC)] administration on sexual responding of ovariectomized, hormone-primed rats. Experiment 2 examined effects of 3 α,5 α-THP administration to the midbrain VTA (100 ng) on fluoxetine-induced decrements in lordosis of ovariectomized, hormone-primed rats and hamsters. MAIN OUTCOME MEASURES: Sexual responding was determined in rats and hamsters. For rats, the percentage of times that the lordosis response occurred following mounting by a sexually-vigorous male (lordosis quotients) was utilized. For hamsters, lateral displacement, the pelvic movement that females will make to facilitate intromissions by a male hamster, was utilized.
RESULTS: Fluoxetine significantly reduced lordosis, and this was reversed SC 3 α,5 α-THP. Intra-VTA 3 α,5 α-THP attenuated fluoxetine's detrimental effects on lordosis quotients and lateral displacement of rats and hamsters, respectively.
CONCLUSIONS: Thus, fluoxetine's effects to disrupt female sexual responses may involve its effects on progestogens in the midbrain VTA.
© 2010 International Society for Sexual Medicine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412429      PMCID: PMC3613153          DOI: 10.1111/j.1743-6109.2010.01814.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  63 in total

Review 1.  3alpha-hydroxy-5alpha-pregnan-20-one in the midbrain ventral tegmental area mediates social, sexual, and affective behaviors.

Authors:  C A Frye; M E Rhodes; S M Petralia; A A Walf; K Sumida; K L Edinger
Journal:  Neuroscience       Date:  2005-12-01       Impact factor: 3.590

2.  SSRI-associated sexual dysfunction.

Authors:  Richard Balon
Journal:  Am J Psychiatry       Date:  2006-09       Impact factor: 18.112

3.  Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis.

Authors:  Nirav R Shah; J B Jones; Jaclyn Aperi; Rachel Shemtov; Anita Karne; Jeff Borenstein
Journal:  Obstet Gynecol       Date:  2008-05       Impact factor: 7.661

4.  Luteinizing hormone receptor mediates neuronal pregnenolone production via up-regulation of steroidogenic acute regulatory protein expression.

Authors:  Tianbing Liu; Jay Wimalasena; Richard L Bowen; Craig S Atwood
Journal:  J Neurochem       Date:  2007-01-11       Impact factor: 5.372

5.  Fluoxetine disrupts food intake and estrous cyclicity in Fischer female rats.

Authors:  Lynda Uphouse; Julie G Hensler; Jhimly Sarkar; Bruce Grossie
Journal:  Brain Res       Date:  2006-01-19       Impact factor: 3.252

6.  Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS).

Authors:  Sandra R Leiblum; Patricia E Koochaki; Cynthia A Rodenberg; Ian P Barton; Raymond C Rosen
Journal:  Menopause       Date:  2006 Jan-Feb       Impact factor: 2.953

Review 7.  Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder.

Authors:  Andrew W Goddard; Anantha Shekhar; Aaron F Whiteman; Christopher J McDougle
Journal:  Drug Discov Today       Date:  2008-02-14       Impact factor: 7.851

8.  Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors.

Authors:  Antonei B Csoka; A Csoka; Audrey Bahrick; Olli-Pekka Mehtonen
Journal:  J Sex Med       Date:  2008-01       Impact factor: 3.802

9.  Mouse major urinary proteins trigger ovulation via the vomeronasal organ.

Authors:  Lorenzo Morè
Journal:  Chem Senses       Date:  2006-03-01       Impact factor: 3.160

10.  Subchronic treatment with fluoxetine attenuates effects of acute fluoxetine on female rat sexual behavior.

Authors:  J Sarkar; C Hiegel; G E Ginis; E Hilbun; L Uphouse
Journal:  Brain Res       Date:  2007-11-28       Impact factor: 3.252

View more
  5 in total

1.  Paroxetine-induced reduction of sexual incentive motivation in female rats is not modified by 5-HT1B or 5-HT2C antagonists.

Authors:  Helge Kaspersen; Anders Agmo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-10       Impact factor: 4.530

Review 2.  Pharmacology of serotonin and female sexual behavior.

Authors:  Lynda Uphouse
Journal:  Pharmacol Biochem Behav       Date:  2013-11-15       Impact factor: 3.533

3.  Effect of newly synthesized 1,2,4-triazino[5,6-b]indole-3-thione derivatives on olfactory bulbectomy induced depression in rats.

Authors:  Urmila M Aswar; Padmaja P Kalshetti; Suhas M Shelke; Sharad H Bhosale; Subhash L Bodhankar
Journal:  Asian Pac J Trop Biomed       Date:  2012-12

4.  Sprague-Dawley and Fischer female rats differ in acute effects of fluoxetine on sexual behavior.

Authors:  Chandra Suma J Miryala; Cindy Hiegel; Lynda Uphouse
Journal:  J Sex Med       Date:  2012-10-30       Impact factor: 3.802

5.  Reports of sexual disorders related to serotonin reuptake inhibitors in the French pharmacovigilance database: an example of underreporting.

Authors:  Thierry Trenque; Géric Maura; Emmanuelle Herlem; Catherine Vallet; Elodie Sole; Pascal Auriche; Moustapha Drame
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.